Enlimomab

Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research[1] [2] .

Product Specifications

CAS Number

[142864-19-5]

Product Name Alternative

BI-RR 0001; Anti-Human IL6 Recombinant Antibody

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/enlimomab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Enlimomab]

Molecular Weight

(147.1 kDa)

References & Citations

[1]J Vuorte, et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol. 1999 Feb 15;162 (4) :2353-7. |[2][2]Gregory J del Zoppo. Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci. 2010 Oct;1207:143-8.